Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADIL Stock Price Chart Interactive Chart >
ADIL Price/Volume Stats
| Current price | $4.18 | 52-week high | $4.78 |
| Prev. close | $4.10 | 52-week low | $1.14 |
| Day low | $4.00 | Volume | 312,922 |
| Day high | $4.25 | Avg. volume | 789,968 |
| 50-day MA | $3.20 | Dividend yield | N/A |
| 200-day MA | $2.57 | Market Cap | 84.85M |
Adial Pharmaceuticals, Inc (ADIL) Company Bio
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Latest ADIL News From Around the Web
Below are the latest news stories about Adial Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of DirectorsHERNDON, Va., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sysorex (OTCQB: SYSX) (“Sysorex” or the “Company”), the preeminent, U.S.-based, publicly traded Ethereum mining and technologies company, today announced that it has elected William B. Stilley, III to the Company’s Board of Directors and as Chair of the Board’s Audit Committee. The Company also expanded the size of its Board to five directors and established its Audit Committee. Mr. Stilley is the Chief Executive Officer of Adial Pharmaceuticals, |
The Daily Biotech Pulse: MacroGenics'' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA''s FDA NodHere''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced completion of patient enrollment in the pivotal phase 3 study of CAN-2409 in prostate cancer) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (announced addition to its board) Caribou Biosciences, Inc. (NASDAQ: CRBU ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Edwards Lifesciences Corporation (NYSE: EW ) Er... |
Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceCHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, will be presenting at the H.C. Wainwright 23 rd Annual Global Investment Conference being held virtually between September 13-15, 2021. |
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderONWARD trial enrollment closed; trial completion expected in Q1 2022 CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302 |
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderONWARD trial enrollment closed; trial completion expected in Q1 2022CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302 patients across 25 clinical sites and has now closed enrollment for its ONWARD™ Phase 3 trial evaluating AD04 a |
ADIL Price Returns
| 1-mo | 27.05% |
| 3-mo | 43.15% |
| 6-mo | 64.57% |
| 1-year | 221.54% |
| 3-year | 43.15% |
| 5-year | N/A |
| YTD | 145.88% |
| 2020 | -29.46% |
| 2019 | -52.93% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...